arginyl-glutamine profile

arginyl-glutamine: attenuates hyperoxia-induced lung injury in neonatal mice [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Arg-Gln : A dipeptide formed from L-arginyl and L-glutamine residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	7019985
CHEBI ID	73813
SCHEMBL ID	268800
MeSH ID	M0582091

Synonym
l-arg-l-gln
l-arginyl-l-glutamine
arginylglutamine
arg-gln
CHEBI:73813
arginyl-glutamine
rq
2483-17-2
l-glutamine, l-arginyl-
SCHEMBL268800
DTXSID30427206
PMGDADKJMCOXHX-BQBZGAKWSA-N
arginine-glutamine dipeptide
arginine glutamine dipeptide
rq dipeptide
r-q dipeptide
(2s)-5-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoic acid
Q27144129
(s)-5-amino-2-((s)-2-amino-5-guanidinopentanamido)-5-oxopentanoic acid
(s)-5-amino-2-((s)-2-amino-5-guanidinopentanamido)-5-oxopentanoicacid
arginyl-glutamine dipeptide
(2s)-5-azanyl-2-(((2r)-2-azanyl-5-carbamimidamido-pentanoyl)amino)-5-oxidanylidene-pentanoic acid
H694N9A9AP

Excerpt	Reference
" Quality of life (EORTC QLQ-C30/PROMS) at baseline and upon radiotherapy at a dosage of 50 Gy were assessed."	( A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer. Hamauchi, S; Mori, K; Ogawa, H; Onitsuka, T; Onoe, T; Suzuki, M; Yamashita, A; Yokota, T; Yoshida, Y; Yurikusa, T, 2018)

Role	Description
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
dipeptide	Any molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (100.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (33.33%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (16.67%)	4.05%
Observational	0 (0.00%)	0.25%
Other	3 (50.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
beta-hydroxyisovaleric acid 3-hydroxyisovaleric acid : A 3-hydroxy monocarboxylic acid that is isovaleric acid substituted at position 3 by a hydroxy group. Used as indicator of biotin deficiency.	4.75	3	2	3-hydroxy monocarboxylic acid	human metabolite
valerates Valerates: Derivatives of valeric acid, including its salts and esters.	4.75	3	2	short-chain fatty acid anion; straight-chain saturated fatty acid anion	plant metabolite
arginylarginine Arg-Arg : A dipeptide formed from two L-arginine residues.	2.11	1	0	dipeptide	Mycoplasma genitalium metabolite
protectin d1 protectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress; structure in first source. protectin D1 : A dihydroxydocosahexaenoic acid that is (4Z,7Z,11E,13E,15Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at positions 10 and 17 (the 10R,17S-stereoisomer). Protectin D1 is one of the specialised proresolving mediators. When produced in neural tissues, it is called neuroprotectin D1	2.17	1	0	dihydroxydocosahexaenoic acid; protectin; secondary allylic alcohol	anti-inflammatory agent; apoptosis inhibitor; hepatoprotective agent; human xenobiotic metabolite; neuroprotective agent; PPARgamma agonist; specialised pro-resolving mediator

Condition	Relationship Strength	Studies	Trials
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.17	1	0
Retrolental Fibroplasia [description not available]	2.17	1	0
Neovascularization, Optic Disc [description not available]	2.17	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.17	1	0
Retinopathy of Prematurity A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)	2.17	1	0
Retinal Neovascularization Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.	2.17	1	0
Cancer of Head [description not available]	4.48	2	2
Mucositis, Oral [description not available]	3.56	1	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	4.48	2	2
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	3.56	1	1
Cancer of Colon [description not available]	2.1	1	0
Cancer of Lung [description not available]	2.1	1	0
Dermatoses [description not available]	2.1	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.1	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.1	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	2.1	1	0
Dermatitis, Radiation-Induced [description not available]	3.48	1	1
Radiodermatitis A cutaneous inflammatory reaction occurring as a result of exposure to ionizing radiation.	3.48	1	1
Genetic Predisposition [description not available]	2.11	1	0
Chronic Kidney Failure [description not available]	2.11	1	0
Kaposi Disease [description not available]	2.11	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	2.11	1	0
Xeroderma Pigmentosum A rare, pigmentary, and atrophic autosomal recessive disease. It is manifested as an extreme photosensitivity to ULTRAVIOLET RAYS as the result of a deficiency in the enzyme that permits excisional repair of ultraviolet-damaged DNA.	2.11	1	0

arginyl-glutamine

Description

Cross-References

Synonyms (23)

Dosage Studied

Roles (1)

Drug Classes (1)

Research

Studies (5)

Study Types